12,006 Shares in Design Therapeutics, Inc. (NASDAQ:DSGN) Acquired by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. acquired a new position in Design Therapeutics, Inc. (NASDAQ:DSGN) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 12,006 shares of the company’s stock, valued at approximately $74,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Paloma Partners Management Co bought a new position in Design Therapeutics in the 3rd quarter worth approximately $64,000. SG Americas Securities LLC bought a new position in Design Therapeutics in the 3rd quarter valued at $66,000. The Manufacturers Life Insurance Company bought a new position in Design Therapeutics in the 3rd quarter valued at $71,000. MetLife Investment Management LLC bought a new stake in shares of Design Therapeutics during the 3rd quarter worth $104,000. Finally, Cubist Systematic Strategies LLC lifted its holdings in shares of Design Therapeutics by 75.6% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 23,497 shares of the company’s stock worth $79,000 after acquiring an additional 10,113 shares during the last quarter. 56.64% of the stock is owned by institutional investors.

Design Therapeutics Stock Performance

NASDAQ DSGN opened at $4.72 on Tuesday. Design Therapeutics, Inc. has a 52-week low of $2.24 and a 52-week high of $7.77. The company has a market capitalization of $267.25 million, a P/E ratio of -5.55 and a beta of 1.79. The company has a fifty day moving average of $5.70 and a 200-day moving average of $5.36.

Design Therapeutics (NASDAQ:DSGN) last issued its earnings results on Thursday, November 7th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.03. As a group, analysts forecast that Design Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.

Design Therapeutics Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.